Publications by authors named "C Bucciarelli-Ducci"

Background: ST-segment elevation myocardial infarction (STEMI) is treated with immediate primary percutaneous coronary intervention (pPCI) to restore coronary blood flow in the acutely ischaemic territory, but is associated with reperfusion injury limiting the benefit of the therapy. No treatment has proven effective in reducing reperfusion injury. Transcoronary hypothermia has been tested in clinical studies and is well tolerated, but is generally established after crossing the occlusion with a guidewire therefore after initial reperfusion, which might have contributed to the neutral outcomes.

View Article and Find Full Text PDF

The pathophysiology of myocardial injury following COVID-19 remains uncertain. COVID-HEART was a prospective, multicentre study utilising cardiovascular magnetic resonance (CMR) to characterise COVID-related myocardial injury. In this pre-specified analysis, the objectives were to examine (1) the frequency of myocardial ischaemia following COVID-19, and (2) the association between ischaemia and myocardial injury.

View Article and Find Full Text PDF

Importance: Development of myocardial fibrosis in patients with aortic stenosis precedes left ventricular decompensation and is associated with an adverse long-term prognosis.

Objective: To investigate whether early valve intervention reduced the incidence of all-cause death or unplanned aortic stenosis-related hospitalization in asymptomatic patients with severe aortic stenosis and myocardial fibrosis.

Design, Setting, And Participants: This prospective, randomized, open-label, masked end point trial was conducted between August 2017 and October 2022 at 24 cardiac centers across the UK and Australia.

View Article and Find Full Text PDF
Article Synopsis
  • The study examined the effects of myocardial injury in hospitalized COVID-19 survivors who had elevated troponin levels, using cardiac imaging and tracking health-related quality of life over 12 months.* -
  • Conducted in 25 UK centers, the research involved 342 participants, finding that while some cardiovascular events occurred, overall major adverse outcomes were low after 12 months.* -
  • Results showed slight improvements in heart function and quality of life after 6 months, with no evidence of ongoing myocardial inflammation or progression of heart injury.*
View Article and Find Full Text PDF